KRAS and Patent ductus arteriosus: PDA initiated by oncogenic KRAS is negative for senescence markers, including p16, p15INK4b, Dec1 and DcR2, while premalignant lesions are positive for those markers, suggesting that senescence exists in premalignant tumors but not in PDA [48].